The increasing need for new and improved vaccines and the growing level of sophistication of their associated adjuvantation and delivery systems has major implications for the design, formulation, delivery, manufacturing and quality assessment of modern vaccines and immune interventions in general. Following the successful MVAF meetings held in Prague, Dublin and Cannes, the follow-up conference MVAF 2013 will offer an international forum for the discussion of all aspects of vaccine formulation and will focus on:

- Innovation in vaccine design and adjuvantation/delivery technologies
- Challenges to manufacturing and the administration of modern vaccines
- Compliances with quality standards and regulatory requirements

MVAF 2013 will then assess the impact of all of the above on the future development/design of vaccines and adjuvants.

MVAF 2013 will be of interest to researchers/contributors from academic programs, industrial, governmental and regulatory groups. Contributions to both the oral and poster programs are encouraged. Potential contributors attention is drawn to the Call For Abstracts on the reverse of this brochure.

**SCIENTIFIC ADVISORY PANEL**

**Conference Chair:**
- Geert van den Bossche (Smart Vaccine Technologies, Seattle, Washington, USA)
- Martin Friede (WHO, Geneva, Switzerland)
- Nathalie Garcon (GSK Biologicals, Belgium)
- Adriana Baz Morell (CSL Ltd, Melbourne, Australia)
- Jean Haensler (Sanofi Pasteur, France)
- Danuta Herzyk (Merck Research Laboratories, USA)
- Mannmohan Singh (Novartis Vaccines, Cambridge, Massachusetts, USA)
- Jan-Willem van der Laan (Medicines Evaluation Board, Utrecht, The Netherlands)
- Lakshmi Khandke (Pfizer Vaccine Research, Pearl River, New York, USA)
- Bruce Weniger (Chiang Mai University, Chiang Mai, Thailand)
- Rob Lambkin-Williams (Retroscreen Virology Ltd, London, UK)
- Gwyn Davies (St. George’s Hospital, London, UK)
- Matthew Downham (Novartis Vaccines & Diagnostics, Siena, Italy)
- Greg Glenn (Novavax Inc., Rockville, Maryland, USA)
- Alan Shaw (Vanderstra Corporation, Cambridge, Massachusetts, USA)
- Niranj Sardesai (Inovio Pharmaceuticals, Blue Bell, Pennsylvania, USA)
- Gary Ott (Dynavax Inc., San Diego, California, USA)
- Heather Davis (Pfizer Vaccines Research, Ottawa, Canada)
- Steve Reed (IDRI, Seattle, Washington, USA)
- Nicolas Collin (University of Lausanne, Lausanne, Switzerland)
- Blaise Genton (CHUV, Lausanne, Switzerland)
- Stephane Ascarateil (SEPPIC, Paris, France)
- Guro Gafvelin (Viscogel AB, Solna, Sweden)

**CONFERENCE SCOPE/TOPICS**

The following list of topics is not exhaustive but reflects the variety of subjects that this area of vaccine/adjuvant technology and development encompasses:

**Innovative Vaccine Concepts and Designs**
- Molecular Approaches to Vaccine Design
- Vaccine Immunology/Immunogenicity Studies
- Vaccine Design & Formulation
- Modelling Methods
- Vaccine/Adjuvant Delivery Issues & Systems
- Vaccine/Adjuvant Diversity – Live or Inactivated Virus/Recombinant Protein
- Polysaccharide or Peptide (free versus conjugated)
- Viral Vectors/DNA Vectors
- VLPs & Nanoparticulate Vaccines
- Administration Devices/Methods (oral/nasal/transcutaneous/needle-free)

**Process & Manufacturing**
- Protein Stabilization/Virus Stabilization/Vaccine Stabilization
- Vaccine Preservation Issues – New/Novel Vaccine Preservatives
- Vaccine Stability Monitoring Methods

**Characterization and quality assessment in compliance with regulatory guidelines**
- Vaccine/Adjuvant Quality, Purity & Potency/Efficacy & Safety
- Safety Evaluation Considerations
- Assay Development Aspects
- Toxicology Studies
- Regulatory Guidelines – National/International for Adjuvanted Vaccines
Abstract Submissions

The MVAF 2013 Scientific Advisory Panel require authors to submit a one page abstract for each paper they wish to be considered for inclusion in the oral and/or poster programs during MVAF 2013. The one page abstract should contain sufficient information for the Scientific Advisory Panel to be able to make a valid decision as to the intrinsic merit of the paper and its relevance to the aims of the conference. Authors should indicate on the reply form whether they prefer oral or poster presentation. Proposals are also invited for panel discussions and special workshops – these special sessions may be scheduled during the daytime conference timetable or alternatively can be allocated as either breakfast or evening sessions.

Abstract proposals should be sent for the attention of John Herriot at Meetings Management (MVAF 2013 Conference Organisers). Authors should send their abstract(s) by e-mail to: jherriot@meetingsmgmt.u-net.com (please attach abstracts as Word documents).

Closing date for submissions intended for oral presentation: Friday 23rd November 2012. Authors will be informed of the status of their contribution(s) in December 2012. Closing date for submissions intended for poster presentation: Friday 19th April 2013.

Publication

Abstracts of all papers to be presented (oral and poster) will be included in a CD ROM which will be distributed to delegates on registration.

Participation

All non-invited speakers will be expected to register as delegates to MVAF 2013. Registration will require speakers to pay a registration fee to attend the conference. Travel and accommodation expenses are the responsibility of each non-invited speaker and no direct compensation is awarded for speakers at MVAF 2013. Your submission of an abstract testifies to the fact that you will accept these financial conditions.

CALL FOR PARTICIPATION REPLY FORM

- I wish to be placed on the mailing list to receive further information on MVAF 2013
- I am interested in presenting a paper/poster (abstract attached) – please indicate preferred presentation method

Title of abstract:

Intended session:

Name: ......................................................... Title (Prof, Dr, Mr, Mrs, Ms): .........................................................
Organisation: ........................................................................
Address: ........................................................................
Postal/Zip Code: ......................................................... Country: .........................................................
Telephone: ......................................................... Fax: .........................................................
E-mail (Please Type/Print): .........................................................

- My organisation is interested in sponsoring MVAF 2013
- Please send me details of exhibition/delegate wallet service

REQUEST DETAILS OF FUTURE EVENTS

- MODERN VACCINES, ADJUVANTS & DELIVERY SYSTEMS – 4-6 July 2012, Copenhagen, Denmark
- INFLUENZA VACCINES FOR THE WORLD – 9-12 October 2012, Valencia, Spain
- VIRUS-LIKE PARTICLE & NANO-PARTICLE VACCINES – 28-30 November 2012, Cannes, France
- MALARIA VACCINES FOR THE WORLD – 22-24 April 2013, Lausanne, Switzerland
- PLANT-BASED VACCINES & ANTIBODIES – 5-7 June 2013, Verona, Italy
- VACCINES FOR ENTERIC DISEASES – 13-15 November 2013, Bangkok, Thailand

PLEASE RETURN THIS FORM TO:

JOHN HERRIOT, MVAF 2013, MEETINGS MANAGEMENT
Unit 6, Hurtmore Heights Commercial Centre, Hurtmore Road, Hurtmore, Godalming, Surrey GU7 2FD, United Kingdom
Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516 E-mail: jherriot@meetingsmgmt.u-net.com
Website: www.meetingsmanagement.com/mvaf_2013

CLOSING DATE FOR ORAL ABSTRACT SUBMISSIONS: 23RD NOVEMBER 2012 | POSTER ABSTRACT SUBMISSIONS: 19TH APRIL 2013